LIPOSYN II 10%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIPOSYN II 10% (LIPOSYN II 10%).
Provides essential fatty acids (linoleic and linolenic) and calories for patients requiring parenteral nutrition; fatty acids are incorporated into cell membranes and serve as precursors for prostaglandins.
| Metabolism | Primarily metabolized in the liver via beta-oxidation; linoleic and linolenic acids are converted to arachidonic acid and eicosapentaenoic acid, respectively, via desaturation and elongation. |
| Excretion | Renal: negligible; biliary/fecal: negligible; metabolized in tissues (e.g., muscle, adipose) via beta-oxidation and re-esterification; CO2 production via tricarboxylic acid cycle accounts for majority of elimination. |
| Half-life | 18–24 hours for clearance of infused triglycerides; terminal elimination half-life of soybean oil emulsion particles is approximately 30 minutes for particles <1 µm, but longer for larger particles (up to several hours); clinical context: prolonged half-life in renal/hepatic impairment. |
| Protein binding | Triglycerides are not protein-bound; however, lipoproteins (VLDL, etc.) are bound to apolipoproteins (e.g., apoE, apoC) in circulation. |
| Volume of Distribution | Vd: 3–5 L (total body), not typically reported in L/kg due to rapid clearance from plasma; clinical meaning: limited extravascular distribution, primarily confined to vascular space. |
| Bioavailability | Intravenous: 100% (administered directly into systemic circulation); not applicable for other routes. |
| Onset of Action | Intravenous: Increased plasma triglyceride levels within 30 minutes; clinical effect (caloric supply) begins immediately upon infusion. |
| Duration of Action | Intravenous: Caloric effect persists as long as infusion continues; metabolic effects (e.g., decreased free fatty acids) last 4–6 hours post-infusion; clinical notes: continuous infusion required for sustained caloric support. |
Intravenous infusion; maximum daily dose of 2.5 g/kg (25 mL/kg) provided as part of parenteral nutrition, typically administered over 12-24 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, reduce dose by 50% and monitor triglycerides and free fatty acids. |
| Liver impairment | Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Contraindicated or use with extreme caution at reduced dose (e.g., 25% of standard) with close monitoring. |
| Pediatric use | Intravenous: 0.5-1 g/kg/day (5-10 mL/kg/day) initially, increase by 0.5 g/kg/day to a maximum of 3 g/kg/day (30 mL/kg/day) as tolerated; administered over 12-24 hours. |
| Geriatric use | Start at the lower end of the dosing range (e.g., 1 g/kg/day) and titrate slowly; monitor serum triglycerides and liver function due to age-related decreased clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LIPOSYN II 10% (LIPOSYN II 10%).
| Breastfeeding | It is not known whether Liposyn II 10% is excreted in human milk. Caution should be exercised when administered to a nursing woman. The M/P ratio is unknown. |
| Teratogenic Risk | Liposyn II 10% is a lipid emulsion used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Use during pregnancy only if clearly needed. Potential fetal risks include those associated with intravenous fat emulsions, such as fat embolism and hypertriglyceridemia, but no specific teratogenic effects are known. |
■ FDA Black Box Warning
Death in preterm infants: Premature infants have limited ability to metabolize lipids; use is contraindicated in infants with hyperbilirubinemia, suspected or confirmed lipid disorders, or thrombocytopenia.
| Serious Effects |
["Hyperlipidemia","Lipoid nephrosis","Acute pancreatitis with hyperlipidemia","Severe hepatic insufficiency","Egg or soybean allergy"]
| Precautions | ["Risk of fat overload syndrome","Hepatic impairment","Pancreatitis","Pulmonary embolism","Allergic reactions (including anaphylaxis)"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of fat overload syndrome (e.g., hepatomegaly, splenomegaly, thrombocytopenia, coagulopathy, hypertriglyceridemia). Monitor serum triglycerides, liver function tests, and platelet count. Assess vital signs and respiratory status for signs of pulmonary embolism. Monitor fetal heart rate and growth if indicated. |
| Fertility Effects | No studies on fertility have been conducted with Liposyn II 10%. There is no known effect on fertility or reproductive capacity. |